Bristol Myers Squibb (NYSE:BMY – Get Free Report) was upgraded by stock analysts at Argus from a “hold” rating to a “buy” rating in a report issued on Wednesday, MarketBeat.com reports. Get Bristol Myers Squibb alerts:View Our Latest Stock Analysis on BMYBristol Myers Squibb Stock PerformanceShares of BMY stock opened at $65.84 on Wednesday. Key Headlines Impacting Bristol Myers SquibbHere are the key news stories impacting Bristol Myers Squibb this week:Positive Sentiment: Reports that AstraZeneca and Bristol Myers Squibb remain in discussions about a potential transaction valued at roughly $400 billion are supporting BMY. Bristol Myers Squibb Sets New 12-Month High on Analyst UpgradeAn analyst upgrade has added to buying interest and helped Bristol Myers Squibb set a fresh 12-month high. Featured StoriesReceive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.